BIOVAIL LABORATORIES INTERNATIONAL S.R.L. Patent applications |
Patent application number | Title | Published |
20110052684 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. | 03-03-2011 |
20100255094 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 10-07-2010 |
20100222435 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT - The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition. | 09-02-2010 |
20100203128 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 08-12-2010 |
20100178353 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON - The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability. | 07-15-2010 |
20100104639 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 04-29-2010 |
20100068270 | BUPROPION HYDROBROMIDE POLYMORPHS - Polymorphous and amorphous forms of bupropion hydrobromide are described. | 03-18-2010 |
20090269402 | MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine. | 10-29-2009 |
20090258067 | MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine. | 10-15-2009 |
20090142378 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 06-04-2009 |
20090118256 | CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF - A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria. | 05-07-2009 |
20090004281 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM - The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core. | 01-01-2009 |
20080274177 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 11-06-2008 |